Trump to sign executive order on psychedelic drug used abroad to treat PTSD
Summary
President Trump plans to sign an executive order to support more U.S. research on ibogaine, a psychedelic drug used abroad to treat PTSD and other conditions. The drug remains illegal in the U.S., but the order aims to allow federal funding for studies, especially to help veterans.Key Facts
- Ibogaine is a natural substance from an African shrub used abroad for PTSD, addiction, and other mental health issues.
- The drug is illegal in the U.S. and classified as Schedule I, meaning it is seen as having no accepted medical use and high abuse risk.
- Americans currently travel to clinics in Mexico and the Caribbean to receive ibogaine treatment.
- President Trump’s executive order will not change the drug’s legal status but will promote more research within the U.S.
- Texas has allocated $50 million for ibogaine research to explore its safety and effectiveness.
- Studies show ibogaine may reduce withdrawal symptoms and PTSD but can cause serious heart problems, including death.
- A small Stanford study combined ibogaine with magnesium to protect the heart, showing some positive effects for veterans.
- There is currently no federal oversight of international clinics where Americans get ibogaine treatments.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
